In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Greenwich LifeSciences (GLSI – Research Report), with a price target of $38.00. The company’s shares opened today at $13.10.
Chen covers the Healthcare sector, focusing on stocks such as Prophase Labs, Veru, and First Wave Bio. According to TipRanks, Chen has an average return of -26.8% and a 25.15% success rate on recommended stocks.
Currently, the analyst consensus on Greenwich LifeSciences is a Moderate Buy with an average price target of $38.00.
See Insiders’ Hot Stocks on TipRanks >>
GLSI market cap is currently $168.7M and has a P/E ratio of -21.52.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GLSI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Greenwich LifeSciences Inc is a clinical stage bio-pharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients.
